BENZAMIDE COMPOUNDS Russian patent published in 2023 - IPC C07D471/04 C07D211/46 C07D295/155 C07D471/14 C07D491/107 A61K31/496 A61K31/5377 A61P35/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. In formula (I): R¹ is selected from the group consisting of hydrogen, halogen, unsubstituted C₁-C₆ alkyl, and unsubstituted C₁-C₆ haloalkyl; each R² is independently unsubstituted C₁-C₆ alkyl; or, when m is 2, each R² is independently unsubstituted C₁-C₆ alkyl, or two R² groups taken together with the atom(s) to which they are attached form an unsubstituted C₃-C₆ cycloalkyl; R³ is X-R^3A; R^3A is an unsubstituted 5–10-membered heteroaryl such as ; R⁴ is NO₂; R⁵ is -X¹-(Alk¹)_n-R⁷; Alk¹ is selected from unsubstituted C₁-C₄ alkylene and C₁-C₄ alkylene substituted with 1, 2 or 3 substituents independently selected from fluorine, chlorine, unsubstituted C₁-C₃ alkyl and unsubstituted C₁-C₃ haloalkyl; R⁷ is selected from substituted or unsubstituted C₃-C₁₀ cycloalkyl and substituted or unsubstituted 3–10-membered heterocyclyl containing 1–2 heteroatoms selected from nitrogen and oxygen; m is either 0, 1 or 2; n is selected from 0 and 1; X¹ is -NH-; and X is -O-. Also the following is provided: a pharmaceutical composition, a method of treating cancer or a tumor, a method of inhibiting the replication of a malignant formation or tumor, a method of inhibiting Bcl-2 activity, and using a compound of formula (I) or a pharmaceutical composition for the manufacture of a medicinal product.

EFFECT: proposed compounds, as well as their pharmaceutically acceptable salts and compositions are used to treat diseases or conditions mediated by Bcl-2 including conditions characterized by excessive cell proliferation, such as cancer and tumors.

35 cl, 7 dwg, 3 tbl, 77 ex